Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
Nektar Therapeutics (NASDAQ GS:NKTR)2/8/2010
most recent headlinesmore headlines:       
TUESDAY, FEBRUARY 02, 2010
4:15 PMNektar Therapeutics Appoints R. Scott Greer to Board of Directors - PR Newswire
TUESDAY, JANUARY 12, 2010
9:00 AMNektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer - PR Newswire
MONDAY, JANUARY 11, 2010
9:00 AMJennerex Appoints Dr. Hoyoung Huh to Its Board of Directors - PR Newswire
WEDNESDAY, JANUARY 06, 2010
5:54 PMNektar Therapeutics Names Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer - PR Newswire
9:00 AMNektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA - PR Newswire
MONDAY, DECEMBER 14, 2009
8:30 AMDennis Winger Joins Nektar Therapeutics' Board of Directors - PR Newswire
MONDAY, NOVEMBER 30, 2009
5:09 PMNektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer - PR Newswire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Cost Basis Calculator  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.